Last reviewed · How we verify
Yasmin (EE30/DRSP, BAY86-5131)
Yasmin (EE30/DRSP, BAY86-5131) is a combined oral contraceptive Small molecule drug developed by Bayer. It is currently in Phase 3 development for Dysmenorrhea, Acne, Hirsutism.
Yasmin is a combination oral contraceptive that works by inhibiting ovulation through the estrogen and progestin components.
Yasmin is a combination oral contraceptive that works by inhibiting ovulation through the estrogen and progestin components. Used for Dysmenorrhea, Acne, Hirsutism.
At a glance
| Generic name | Yasmin (EE30/DRSP, BAY86-5131) |
|---|---|
| Sponsor | Bayer |
| Drug class | combined oral contraceptive |
| Modality | Small molecule |
| Therapeutic area | Women's Health |
| Phase | Phase 3 |
Mechanism of action
The estrogen component, ethinyl estradiol, suppresses the release of gonadotropin-releasing hormone, which in turn inhibits the release of follicle-stimulating hormone and luteinizing hormone. The progestin component, drospirenone, has anti-androgenic and anti-mineralocorticoid effects, which contribute to its contraceptive efficacy.
Approved indications
- Dysmenorrhea
- Acne
- Hirsutism
- Dysfunctional uterine bleeding
- Emergency contraception
Common side effects
- Nausea
- Headache
- Breast tenderness
- Vaginal bleeding irregularities
- Mood changes
Key clinical trials
- LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study (PHASE3)
- Yasmin Post Marketing Surveillance
- Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being
- Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin) (PHASE1)
- Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yasmin (EE30/DRSP, BAY86-5131) CI brief — competitive landscape report
- Yasmin (EE30/DRSP, BAY86-5131) updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Yasmin (EE30/DRSP, BAY86-5131)
What is Yasmin (EE30/DRSP, BAY86-5131)?
How does Yasmin (EE30/DRSP, BAY86-5131) work?
What is Yasmin (EE30/DRSP, BAY86-5131) used for?
Who makes Yasmin (EE30/DRSP, BAY86-5131)?
What drug class is Yasmin (EE30/DRSP, BAY86-5131) in?
What development phase is Yasmin (EE30/DRSP, BAY86-5131) in?
What are the side effects of Yasmin (EE30/DRSP, BAY86-5131)?
Related
- Drug class: All combined oral contraceptive drugs
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Women's Health
- Indication: Drugs for Dysmenorrhea
- Indication: Drugs for Acne
- Indication: Drugs for Hirsutism
- Compare: Yasmin (EE30/DRSP, BAY86-5131) vs similar drugs
- Pricing: Yasmin (EE30/DRSP, BAY86-5131) cost, discount & access